- Trial phase
- Approved
- Time to market
- Already on the market since 2011. The drug has lost U.S. market exclusivity and faces multiple generic entrants.
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for DIFICID in the next 12 months. It is an already-approved, marketed drug with no pending regulatory decision. The commercial story is generic erosion, not a binary event. DIFICID is also a very small part of Merck's $66B+ annual revenue, so even a large sales swing would not materially move MRK shares.
DIFICID is a post-exclusivity product in rapid decline. For MRK investors, the drug is not a material catalyst in either direction. Watch for continued generic erosion in quarterly earnings releases, but the real MRK story remains Keytruda's patent cliff (2028) and pipeline replacement, not DIFICID.
Price Chart
Executive Summary
DIFICID (fidaxomicin) is Merck's antibiotic for C. difficile-associated diarrhea, first approved in 2011. The drug lost U.S. market exclusivity in July 2025 when Teva launched an AB-rated generic, triggering a sharp revenue decline (sales down 77% in Q2 2026). Multiple additional generic entrants, including Sandoz (approved August 2026), are accelerating the erosion. DIFICID is a mature product with no upcoming binary catalysts and represents a negligible portion of Merck's overall revenue, making it a low-impact asset for MRK investors.
How It Works
DIFICID is an oral antibiotic that works locally in the gut to kill C. difficile bacteria while causing minimal disruption to the rest of the body's microbiome. It is a macrolide that inhibits bacterial RNA polymerase, stopping the bacteria from multiplying.
Trial Status
DIFICID was initially FDA-approved in 2011 for adults with C. difficile-associated diarrhea (CDAD). A pediatric indication (ages 6 months and older) and an oral suspension formulation were approved around 2020 based on the Phase 3 SUNSHINE study (NCT02218372). The drug is now a mature, marketed product facing generic competition.
The Two-Sided Case
Upcoming Catalysts
- No binary catalysts scheduled for DIFICID specifically. The drug is an approved, marketed product facing generic erosion. Any catalyst would be commercial (sales trends, guideline updates) rather than regulatory.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report